Literature DB >> 3147151

Isotypy of serum monoclonal immunoglobulins in human immunodeficiency virus-infected adults.

S Briault1, M Courtois-Capella, F Duarte, P Aucouturier, J L Preud'Homme.   

Abstract

The classes, subclasses and light chain types of 78 serum monoclonal immunoglobulins (MoIg) from adult patients affected with various clinical forms of human immunodeficiency virus (HIV) infection were studied by a sensitive Western blot technique. The incidence of MoIg-containing sera was 26% in a systematic study. Most of these sera contained several (up to eight) detectable MoIg. These MoIg were IgG (91%) and IgM (9%) with a predominance of light chains of the lambda type (kappa:lambda ratio 0.6). The subclass distribution of monoclonal IgG was strikingly different from that observed in myeloma; much less IgG1 and much more IgG3 and IgG4.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147151      PMCID: PMC1541791     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  Oligoclonal immunoglobulins in the sera of healthy subjects at risk for AIDS.

Authors:  N M Papadopoulos; R Costello
Journal:  Clin Biochem       Date:  1987-08       Impact factor: 3.281

2.  Monoclonal gammopathies in asymptomatic HIV-seropositive patients.

Authors:  J J Lefrere; J M Fine; P Lambin; J Y Muller; A M Courouce; C Salmon
Journal:  Clin Chem       Date:  1987-09       Impact factor: 8.327

3.  [Serum monoclonal immunoglobulins and HIV-I infection].

Authors:  D Bouscary; R Fior; L Intrator; C Picard; A Sobel
Journal:  Presse Med       Date:  1987-06-20       Impact factor: 1.228

Review 4.  AIDS--an immunologic reevaluation.

Authors:  M Seligmann; L Chess; J L Fahey; A S Fauci; P J Lachmann; J L'Age-Stehr; J Ngu; A J Pinching; F S Rosen; T J Spira
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

5.  Monoclonal-oligoclonal immunoglobulins in HTLV III infected subjects: HTLV III-induced or HTLV III-associated?

Authors:  P G Sala; S Mazzolini; E Tonutti; C Crucil; E Pitzus; M Bramezza
Journal:  Boll Ist Sieroter Milan       Date:  1987

6.  Pathogenesis of B cell lymphoma in a patient with AIDS.

Authors:  J E Groopman; J L Sullivan; C Mulder; D Ginsburg; S H Orkin; C J O'Hara; K Falchuk; F Wong-Staal; R C Gallo
Journal:  Blood       Date:  1986-03       Impact factor: 22.113

7.  Oligoclonal immunoglobulins in patients with the acquired immunodeficiency syndrome.

Authors:  N M Papadopoulos; H C Lane; R Costello; H M Moutsopoulos; H Masur; E P Gelmann; A S Fauci
Journal:  Clin Immunol Immunopathol       Date:  1985-04

8.  Paraproteinemia in patients with acquired immunodeficiency syndrome (AIDS) or lymphadenopathy syndrome (LAS).

Authors:  K Heriot; A E Hallquist; R H Tomar
Journal:  Clin Chem       Date:  1985-07       Impact factor: 8.327

9.  Serum immunoglobulin G subclass dysbalances in the lymphadenopathy syndrome and acquired immune deficiency syndrome.

Authors:  P Aucouturier; L J Couderc; D Gouet; F Danon; J Gombert; S Matheron; A G Saimot; J P Clauvel; J L Preud'homme
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

10.  Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis.

Authors:  P G Pelicci; D M Knowles; Z A Arlin; R Wieczorek; P Luciw; D Dina; C Basilico; R Dalla-Favera
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

  10 in total
  9 in total

1.  Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease.

Authors:  M Cogné; J L Preud'homme; M Bauwens; G Touchard; P Aucouturier
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  HIV is trapped and masked in the cytoplasm of lymph node follicular dendritic cells.

Authors:  C Tacchetti; A Favre; L Moresco; P Meszaros; P Luzzi; M Truini; F Rizzo; C E Grossi; E Ciccone
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 3.  Prevalence of monoclonal gammopathy of undetermined significance: a systematic review.

Authors:  Rishi K Wadhera; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2010-08-16       Impact factor: 7.616

4.  Human monoclonal IgM with autoantibody activity against two gangliosides (GM1 and GD1b) in a patient with motor neuron syndrome.

Authors:  M O Jauberteau; N Gualde; J L Preud'Homme; M Rigaud; R Gil; J M Vallat; N Baumann
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

5.  Development of multiple monoclonal serum immunoglobulins (multiclonal gammopathy) following both HLA-identical unfractionated and T cell-depleted haploidentical bone marrow transplantation in severe combined immunodeficiency.

Authors:  E F Kent; J Crawford; H J Cohen; R H Buckley
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

6.  λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies.

Authors:  Mohammad M Sajadi; Maham Farshidpour; Eric P Brown; Xin Ouyang; Michael S Seaman; Marzena Pazgier; Margaret E Ackerman; Harriet Robinson; Georgia Tomaras; Matthew S Parsons; Manhattan Charurat; Anthony L DeVico; Robert R Redfield; George K Lewis
Journal:  J Infect Dis       Date:  2015-09-07       Impact factor: 5.226

7.  Plasma Cell Disorders in HIV Infected Patients: A Case Series.

Authors:  S Anuradha; Prayas Sethi
Journal:  J Clin Diagn Res       Date:  2017-06-01

8.  Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.

Authors:  Woodrow J Coker; Ashley Jeter; Henning Schade; Yubin Kang
Journal:  Biomark Res       Date:  2013-02-04

Review 9.  Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients.

Authors:  Jessica Caro; Marc Braunstein; Louis Williams; Benedetto Bruno; David Kaminetzky; Ariel Siegel; Beatrice Razzo; Serge Alfandari; Gareth J Morgan; Faith E Davies; Eileen M Boyle
Journal:  Leukemia       Date:  2022-02-02       Impact factor: 12.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.